Companies Dominating the Advanced Renal Cell Carcinoma Treatment Landscape
- Ono Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Bristol Myers Squibb Company
- Bayer AG
- Pfizer Inc.
- AbbVie Inc.
- Teva Pharmaceuticals Industries Ltd.
Browse Key Market Insights with Data Illustration:
In the News
-
Bristol Myers Squibb Company and Exelixis, Inc. reported three-year follow-up results from the Phase 3 CheckMate-9ER trial. Compared to sunitinib, Opdivo (nivolumab) and CABOMETYX (cabozantinib) have demonstrated sustained survival and response rates when used as a first-line treatment for advanced renal cell carcinoma (RCC).
-
Merck & Co., Inc’s anti-PD-1 therapy KEYTRUDA has been approved by FDA for use as adjuvant therapy in patients with renal cell carcinoma (RCC) at intermediate-high or high recurrence risk following nephrectomy, or following nephrectomy and metastatic resection.
